药理干预措施用于治疗阻塞性睡眠呼吸暂停综合征
Jin Liu1, Xiaolan Yang2, Guangcai Li3
1Department of Central Hospital of Tujia and Miao Autonomous Prefecture, Hubei University of Medicine, Shiyan, China.
Frontiers in medicine
|March 18, 2024
概括
药物治疗对阻断性睡眠呼吸暂停综合征 (OSAS) 有希望,改善关键指标,如呼吸暂停-呼吸暂停指数 (AHI) 和减少嗜睡. 这些进展为管理这种常见的睡眠障碍提供了新的希望.
科学领域:
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 阻塞性睡眠呼吸暂停综合征 (OSAS) 影响了全球大量人口,对如连续正气道压力 (CPAP) 等当前治疗提出了挑战.
- 对CPAP的不良坚持和持续的过度嗜睡是OSAS管理的主要障碍.
- 新兴的研究探索药理干预措施,以解决这些未满足的需求.
研究的目的:
- 审查阻断性睡眠呼吸暂停综合征 (OSAS) 药理疗法的最新进展.
- 分析临床试验,研究用于改善OSAS症状和改善睡眠质量的药物.
- 在OSAS管理中提供药物研究的全面概述.
主要方法:
- 对OSAS的药理学药物的临床试验进行系统审查.
- 药物的分析,包括多巴胺再吸收抑制剂,上腺素抑制剂,抗肌糖类药物和素激动剂.
- 对呼吸指标和睡眠质量指标的影响评估.
主要成果:
- 研究的药理学药物显示出改善呼吸暂停-呼吸暂停指数 (AHI) 的潜力.
- 在爱普沃思睡眠度量 (ESS) 中观察到改善,表明白天睡眠减少.
- 这些发现表明,OSAS患者的症状管理和睡眠质量得到了改善.
结论:
- 药理干预是OSAS的新兴和有前途的治疗方向.
- 目前的药物研究显示了有效管理OSAS复杂挑战的潜力.
- 在这个领域的进一步发展可以显著改善患者的治疗结果和治疗坚持.
相关概念视频
01:21Sleep Apnea
151
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
151
01:19Management of Insomnia
244
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
244
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
171
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
171
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:23Sedatives and Hypnotics: Overview
359
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
359
01:26COPD: Management Using Bronchodilators and Corticosteroids
205
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
205